### 2.2.1 In vitro and physicochemical data

A literature search was performed to collect available information on physicochemical properties of sildenafil. The obtained information from literature is summarized in the table below, and is used for model building.

| **Parameter**                         | **Unit**                   | **Value**        | Source                            | **Description**                                              |
| :------------------------------------ | -------------------------- | ---------------- | --------------------------------- | ------------------------------------------------------------ |
| MW                                    | g/mol                      | 474.576          | [DrugBank DB00203](#5-references) | Molecular weight                                             |
| pK<sub>a1</sub>                       |                            | 5.97             | [Salerno 2021](#5-references)     | Acid dissociation constant of conjugate acid; compound type: basic |
| pK<sub>a1</sub>                       |                            | 6.78             | [Gobry 2000](#5-references)       | Acid dissociation constant of conjugate acid; compound type: ampholyte |
| pK<sub>a2</sub>                       |                            | 9.12             | [Gobry 2000](#5-references)       | Acid dissociation constant of conjugate acid; compound type: ampholyte |
| Solubility (pH)                       | mg/mL                      | 0.025<br />(7.1) | [Takano 2016](#5-references)      | Aqueous Solubility                                           |
|                                       |                            | 3.5              | [Salerno 2021](#5-references)     | Aqueous Solubility                                           |
|                                       |                            | 3.5              | [DrugBank DB00203](#5-references) | Aqueous Solubility                                           |
|                                       |                            | 4.1              | [Jung 2011](#5-references)        | Aqueous Solubility                                           |
|                                       |                            | 3.965<br />(3)   | [Wang 2008](#5-references)        | Aqueous Solubility                                           |
|                                       |                            | 7.077<br />(4)   | [Wang 2008](#5-references)        | Aqueous Solubility                                           |
|                                       |                            | 2.068<br />(5)   | [Wang 2008](#5-references)        | Aqueous Solubility                                           |
|                                       |                            | 0.114<br />(6)   | [Wang 2008](#5-references)        | Aqueous Solubility                                           |
|                                       |                            | 0.025<br />(7)   | [Wang 2008](#5-references)        | Aqueous Solubility                                           |
|                                       |                            | 0.027<br />(8)   | [Wang 2008](#5-references)        | Aqueous Solubility                                           |
|                                       |                            | 0.04<br />(9)    | [Wang 2008](#5-references)        | Aqueous Solubility                                           |
|                                       |                            | 0.103<br />(10)  | [Wang 2008](#5-references)        | Aqueous Solubility                                           |
|                                       |                            | 0.322<br />(11)  | [Wang 2008](#5-references)        | Aqueous Solubility                                           |
| logP                                  |                            | 3.18             | [Gobry 2000](#5-references)       | Partition coefficient between octanol and water              |
|                                       |                            | 2.70             | [Takano 2016](#5-references)      | Partition coefficient between octanol and water              |
|                                       |                            | 2.70             | [Walker 1999](#5-references)      | Partition coefficient between octanol and water              |
|                                       |                            | 2.24             | [Wang 2008](#5-references)        | Partition coefficient between octanol and water              |
|                                       |                            | 1.59             | [Wang 2008](#5-references)        | Partition coefficient between octanol and water              |
|                                       |                            | 1.8              | [DrugBank DB00203](#5-references) | Partition coefficient between octanol and water              |
|                                       |                            | 1.87             | [DrugBank DB00203](#5-references) | Partition coefficient between octanol and water              |
| fu                                    | %                          | 4                | [Walker 1999](#5-references)      | Fraction unbound in plasma (α1-acid glycoprotein)            |
|                                       | %                          | 4.3              | [Muirhead 2002b](#5-references)    | Fraction unbound in plasma (α1-acid glycoprotein)            |
|                                       | %                          | 2.7              | [Muirhead 2002b](#5-references)    | Fraction unbound in plasma (α1-acid glycoprotein)            |
|                                       | %                          | 3.46             | [Muirhead 2002b](#5-references)    | Fraction unbound in plasma (α1-acid glycoprotein)            |
| V<sub>max</sub>, K<sub>m</sub> CYP3A4 | pmol/min/pmol P450,<br />µmol/L | 78.6<br />4.34   | [Takano 2016](#5-references)      | Recombinant CYP3A4 Michaelis-Menten kinetics                 |
| V<sub>max</sub>, K<sub>m</sub> CYP3A4 | relative units,<br />µmol/L| 1.9<br />23.10   | [Warrington 2000](#5-references)  | Recombinant CYP3A4 Michaelis-Menten kinetics                 |   
| V<sub>max</sub>, K<sub>m</sub> CYP2C9 | relative units,<br />µmol/L| 0.2<br />9.60    | [Warrington 2000](#5-references)  | Recombinant CYP3A4 Michaelis-Menten kinetics                 |
| V<sub>max</sub>, K<sub>m</sub> CYP2C19| relative units,<br />µmol/L| 0.02<br />23.10  | [Warrington 2000](#5-references)  | Recombinant CYP3A4 Michaelis-Menten kinetics                 |              


### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on sildenafil in adults. 

The following publications were found in adults for model building:

| Publication                            | Arm / Treatment / Information used for model building                                                                                                |
| :------------------------------------- | :--------------------------------------------------------------------------------------------------------------------------------------------------- |
| [Muirhead 2002a](#5-references)         | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil 25 mg intravenous infusion                                   |
| [Nichols 2002](#5-references)          | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil:<br />- 50 mg intravenous infusion <br />- 100mg oral tablet |
| [FDA 2009](#5-references) | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil:<br />- 20 mg intravenous infusion <br />- 40 mg intravenous infusion <br />- 80 mg intravenous infusion|
| [Walker 1999](#5-references)           | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil 50 mg oral solution                                          |
| [Spence 2008](#5-references)           | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil 20 mg tablet                                                 |
| [Lee 2021](#5-references)              | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil:<br />- 25 mg tablet (in the absence of itraconazole)<br />- 25 mg tablet (in the absence of clarithromycin)|
| [Abdelkawy 2016](#5-references)        | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil 50 mg tablet                                                 |
| [Gillen 2017](#5-references)           | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil 50 mg tablet (Panel 1)                                       |
| [Jetter 2002](#5-references)           | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil 50 mg tablet                                                 |
| [Murtadha 2021](#5-references)         | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil 50 mg tablet (non-smoker group)                              |
| [Wilner 2002](#5-references)           | Plasma PK profiles in healthy subjects with single dose administrations of a sildenafil 50 mg tablet (study I)                                       |


The following dosing scenarios were simulated and compared to respective data for model verification:

| Scenario                                                     | Data reference                       |
| ------------------------------------------------------------ | ------------------------------------ |
| po SD 50mg                                                   | [Al-Ghazawi 2010](#5-references)     |
|                                                              | [Hedaya 2006](#5-references)         |
|                                                              | [Wilner 2002](#5-references)         |
|                                                              | [Gillen 2017](#5-references)         |
| po SD 100mg                                                  | [Muirhead 2000](#5-references)       |
| po MD 20/80 mg                                               | [Burgess 2008](#5-references)        |
| po MD 20 mg                                                  | [Gotzkowsky 2013](#5-references)     |

 